Marinus Appoints Michael R. Dougherty to its Board of Directors
February 01 2017 - 7:30AM
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical
company dedicated to the development of innovative therapeutics to
treat epilepsy and neuropsychiatric disorders, today announced the
appointment of Michael R. Dougherty to its Board of Directors.
“Mike is a seasoned executive with extensive
experience in executive leadership, finance, and operations within
the life sciences industry,” commented Christopher M. Cashman,
chief executive officer of Marinus Pharmaceuticals. “His
skills and expertise will complement those of our other board
members as we look to advance the clinical development of
ganaxolone in patients suffering from seizures and
depression.”
Mr. Dougherty has over 30 years of experience in
the biopharmaceutical industry, most recently serving as executive
chairman of Celator Pharmaceuticals, Inc. Prior to Celator, Mr.
Dougherty was chief executive officer and a member of the board of
directors of Kalidex Pharmaceuticals, Inc. Mr. Dougherty also
served in a number of capacities during his ten-year tenure at
Adolor Corporation, including president and chief executive
officer, member of the board of directors, senior vice president of
commercial, chief operating officer, and chief financial officer.
Prior to Adolor, Mike was president and chief operating officer of
Genomics Collaborative, Inc. and served in a variety of senior
positions at Genaera Corporation, including president and chief
executive officer, and at Centocor, Inc. Mr. Dougherty is
currently on the board of directors at Trevena, Inc., Aviragen
Therapeutics, Cempra, Inc., and Foundation Medicine Inc.
Mr. Dougherty received a bachelor’s degree from
Villanova University.
“This is an exciting time to join the Marinus
board,” commented Mr. Dougherty. “Marinus is positioned to
execute on several clinical studies with near-term
milestones. I look forward to working with the Marinus board
and management as we advance the development of the ganaxolone
franchise.”
About Marinus
Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the development of
ganaxolone, which offers a new mechanism of action, demonstrated
efficacy and safety, and convenient dosing to improve the lives of
patients suffering from epilepsy and neuropsychiatric disorders.
Ganaxolone is a CNS-selective GABAA modulator that acts on a
well-characterized target in the brain known to have both
anti-seizure and anti-anxiety effects. Ganaxolone is being
developed in three different dose forms (IV, capsule, and liquid)
intended to maximize therapeutic reach to adult and pediatric
patient populations in both acute and chronic care settings.
Marinus is currently evaluating ganaxolone in orphan pediatric
indications for the treatment of genetic seizure and behavior
disorders, and preparing to initiate Phase 2 studies in status
epilepticus, an orphan indication, and postpartum depression. For
more information visit www.marinuspharma.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Marinus, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “may”, “will”, “expect”, “anticipate”,
“estimate”, “intend”, “believe”, and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of clinical and preclinical studies, assessment
of positive nature and notability of preliminary data,
development plans for our product candidate, including the
development of dose forms, the clinical trial testing schedule and
milestones, the ability to complete enrollment in our clinical
trials, interpretation of scientific basis for ganaxolone use,
timing for availability and release of data, the safety, potential
efficacy and therapeutic potential of our product candidate and our
expectation regarding the sufficiency of our working capital.
Forward-looking statements in this release involve substantial
risks and uncertainties that could cause our clinical development
programs, future results, performance or achievements to differ
significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties
include, among others, the uncertainties inherent in the conduct of
future clinical trials, the timing of the clinical trials,
enrollment in clinical trials, availability of data from ongoing
clinical trials, expectations for regulatory approvals, and other
matters, including the development of formulations of ganaxolone,
that could affect the availability or commercial potential of our
drug candidates. Marinus undertakes no obligation to update
or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of the
Company in general, see filings Marinus has made with the
Securities and Exchange Commission.
CONTACT:
Lisa M. Caperelli
Executive Director, Investor and Strategic Relations
Marinus Pharmaceuticals, Inc.
484-801-4674
lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024